title: Twelve-month consumption of a polyphenol extract from olive (Olea europaea) in a double blind, randomized trial increases serum total osteocalcin levels and improves serum lipid profiles in postmenopausal women with osteopenia.
abstract: OBJECTIVE
  Osteoporosis is a skeletal disorder characterized by impaired bone turnover and compromised bone strength, thereby predisposing to increased risk of fracture. Preclinical research has shown that compounds produced by the olive tree (Olea europaea), may protect from bone loss, by increasing osteoblast activity at the expense of adipocyte formation. The aim of this exploratory study was to obtain a first insight on the effect of intake of an olive extract on bone turnover in postmenopausal women with decreased bone mass (osteopenia).
  
  
  METHODS
  For that, a double blind, placebo-controlled study was performed in which participants were randomly allocated to either treatment or placebo groups.
  
  
  METHODS
  64 osteopenic patients, with a mean bone mineral density (BMD) T-score between -1.5 and -2.5 in the lumbar spine (L2-L4) were included in the study.
  
  
  METHODS
  PARTICIPANTS received for 12 months daily either 250 mg/day of olive extract and 1000 mg Ca (treatment) or 1000 mg Ca alone (placebo). Primary endpoints consisted of evaluation of bone turnover markers. Secondary endpoints included BMD measurements and blood lipid profiles.
  
  
  RESULTS
  After 12 months, the levels of the pro-osteoblastic marker osteocalcin were found to significantly increase in the treatment group as compared to placebo. Simultaneously, BMD decreased in the placebo group, while remaining stable in the treatment group. In addition, improved lipid profiles were observed, with significant decrease in total- and LDL-cholesterol in the treatment group.
  
  
  CONCLUSIONS
  This exploratory study supports preclinical observations and warrants further research by showing that a specific olive polyphenol extract (Bonolive®) affects serum osteocalcin levels and may stabilize lumbar spine BMD. Moreover, the improved blood lipid profiles suggest additional health benefits associated to the intake of the olive polyphenol extract.
authors.affiliation: Sam Possemiers (Ph.D.), BioActor BV, Oxfordlaan 70, 6229-EV Maastricht, The Netherlands; Tel.: +31437114555; FAX: +31433885889; email: sam.possemiers@bioactor.com.
authors.forename: R
authors.initials: R
authors.lastname: Filip
authors.forename: S
authors.initials: S
authors.lastname: Possemiers
authors.forename: A
authors.initials: A
authors.lastname: Heyerick
authors.forename: I
authors.initials: I
authors.lastname: Pinheiro
authors.forename: G
authors.initials: G
authors.lastname: Raszewski
authors.forename: M-J
authors.initials: MJ
authors.lastname: Davicco
authors.forename: V
authors.initials: V
authors.lastname: Coxam
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000097:blood* / Q000188:drug therapy / Q000517:prevention & control; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D057888:Iridoid Glucosides; D039823:Iridoids / Q000008:administration & dosage / Q000494:pharmacology; D008055:Lipids / Q000097:blood*; D008159:Lumbar Vertebrae / Q000187:drug effects; D008875:Middle Aged; D031658:Olea / Q000737:chemistry*; D015675:Osteocalcin / Q000097:blood*; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000517:prevention & control; D008517:Phytotherapy; D010919:Placebos; D010936:Plant Extracts / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology; D059808:Polyphenols / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D017698:Postmenopause / Q000097:blood*; D013997:Time Factors
chemical_list: D015415:Biomarkers; C000601880:Bonolive; D057888:Iridoid Glucosides; D039823:Iridoids; D008055:Lipids; D010919:Placebos; D010936:Plant Extracts; D059808:Polyphenols; D015675:Osteocalcin; C002769:oleuropein